EBMT 2024 | EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter’s transformation
Valentin Ortiz-Maldonado
• 16 Apr 2024
Valentin Ortiz-Maldonado, MD, introduces the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investigated GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). Patients enrolled in the study received a freshly manufactured product, with a median vein-to-vein time of 7 days. This CAR-T therapy showed encouraging efficacy with a tolerable safety profile. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
